Last reviewed · How we verify

Rectal bacteriotherapy — Competitive Intelligence Brief

Rectal bacteriotherapy (Rectal bacteriotherapy) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Gastroenterology.

phase 3 Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Rectal bacteriotherapy (Rectal bacteriotherapy) — Hvidovre University Hospital. Rectal bacteriotherapy involves the administration of beneficial bacteria to the rectum to restore the balance of gut microbiota.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Rectal bacteriotherapy TARGET Rectal bacteriotherapy Hvidovre University Hospital phase 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rectal bacteriotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/rectal-bacteriotherapy. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: